I. Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1-12. (Canceled)

13. (Currently Amended) A pharmaceutical dosage form consisting essentially of ~~comprising~~ an immediate release and a controlled release component, wherein said immediate release component comprises a $GABA_B$ agonist and at least one ~~a~~ pharmaceutically acceptable excipient, and said controlled release component consisting essentially of a $GABA_B$ agonist, at least one pharmaceutically acceptable excipient, and a controlled release material selected from the group consisting of an acrylic polymer, an alkylcellulose, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, a hydroxyalkylcellulose, and a combination thereof; wherein said immediate release component exhibits an in vitro dissolution profile comprising at least about 80% $GABA_B$ agonist release after 1 hour in simulated gastric fluid; wherein said controlled release component exhibits an in vitro dissolution profile in simulated gastric fluid/simulated intestinal fluid (1 hour switchover) medium comprising from about 2% to about 90% $GABA_B$ agonist release after 1 hour, at least about 30% $GABA_B$ agonist release after 4 hours, and at least about 40% $GABA_B$ agonist release after 6 hours; wherein the dosage form releases at least 25% $GABA_B$ agonist in the intestinal tract; and wherein the ratio of said immediate release component to said controlled release component is from about 1:10 to about 10:1.

14. (Original) A pharmaceutical dosage form according to claim 13 wherein said ratio of immediate release component to controlled release component is from about 1:4 to about 4:1.

15. (Original) A pharmaceutical dosage form according to claim 13 wherein said ratio of immediate release component to controlled release component is from about 1:2 to about 1:1.

16. (Original) A pharmaceutical dosage form according to claim 13 wherein said $GABA_B$ agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

17. (Original) A pharmaceutical dosage form according to claim 16 wherein said baclofen is a racemic mixture.

18. (Withdrawn) A pharmaceutical dosage form according to claim 16 wherein said baclofen consists essentially of the L-baclofen enantiomer.

19. (Withdrawn) A pharmaceutical dosage form according to claim 16 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

20. (Original) A pharmaceutical dosage form according to claim 16 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

21. (Original) A pharmaceutical dosage form according to claim 16 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

22. (Withdrawn) A pharmaceutical dosage form according to claim 13 wherein said dosage form is a tablet.

23. (Currently Amended) A pharmaceutical dosage form according to claim 13 wherein said dosage form is contained in a capsule.

24. (Currently Amended) A pharmaceutical dosage form according to claim 23 wherein said immediate and controlled release components are in the form of ~~capsule further~~

~~comprises~~ discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

25-57. (Canceled)

58. (New) A pharmaceutical dosage form consisting of an immediate release and a controlled release component, wherein said immediate release component comprises a $GABA_B$ agonist and at least one pharmaceutically acceptable excipient, and said controlled release component consisting of a $GABA_B$ agonist, at least one pharmaceutically acceptable excipient, and a controlled release material selected from the group consisting of an acrylic polymer, an alkylcellulose, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, a hydroxyalkylcellulose, and a combination thereof; wherein said immediate release component exhibits an in vitro dissolution profile comprising at least about 80% $GABA_B$ agonist release after 1 hour in simulated gastric fluid; wherein said controlled release component exhibits an in vitro dissolution profile in simulated gastric fluid/simulated intestinal fluid (1 hour switchover) medium comprising from about 2% to about 90% $GABA_B$ agonist release after 1 hour, at least about 30% $GABA_B$ agonist release after 4 hours, and at least about 40% $GABA_B$ agonist release after 6 hours; wherein the dosage form releases at least 25% $GABA_B$ agonist in the intestinal tract; and wherein the ratio of said immediate release component to said controlled release component is from about 1:10 to about 10:1.

59. (New) A pharmaceutical dosage form according to claim 58 wherein said dosage form is contained in a capsule.